Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro

Citation
Nj. Curtin et Dp. Turner, Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro, EUR J CANC, 35(6), 1999, pp. 1020-1026
Citations number
38
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
EUROPEAN JOURNAL OF CANCER
ISSN journal
09598049 → ACNP
Volume
35
Issue
6
Year of publication
1999
Pages
1020 - 1026
Database
ISI
SICI code
0959-8049(199906)35:6<1020:DROMRI>2.0.ZU;2-Y
Abstract
Expression of the multidrug resistance-associated protein (MRP) is widespre ad in human malignancies, high levels are associated with poor prognosis an d may be responsible for intrinsic and radiotherapy-induced chemoresistance . In this study, the nucleoside transport inhibitor, dipyridamole (DP), was investigated as a chemosensitiser of MRP. In growth inhibition assays MRP- overexpressing COR L23/R cells were 20 times more resistant to VP16 and dox orubicin compared with the parental COR L23/R human lung carcinoma cells. D P caused an approximately 8-fold sensitisation of the resistant cells and a 2-fold sensitisation of the parental cells. DP enhanced the accumulation o f VP16 1.5 to 2-fold in the parental cells, but had only a modest effect on VP16 accumulation in the resistant cells. VP16 efflux was rapid in both ce ll lines. DP caused a modest and transient inhibition of the initial efflux in the resistant cells but not the parental cells. Incubation with DP caus ed a progressive decrease in GSH levels which was more rapid and profound i n COR L23/R cells than in COR L23/P cells. Thus, chemosensitisation to VP16 by DP in MRP-overexpressing COR L23/R cells appears to be caused by deplet ion of cellular GSH rather than a direct effect of DP on MRP-mediated drug accumulation and efflux. (C), 1999 Elsevier Science Ltd. All rights reserve d.